Personalized Medicine, Heredity Ethical Debate -- an excerpt from a book by Francis Collins
An excerpt from the audiobook "The Language of God: A Scientist Presents Evidence for Belief" (2006) by physician-geneticist Francis Collins (appendix sectio...

By: Byenia

Read more from the original source:
Personalized Medicine, Heredity

Recommendation and review posted by sam

GM5: Mission Health Personalized Medicine and Pharmacogenomics, Asheville, NC - Lynn Dressler
May 28-29, 2013 - Genomic Medicine Centers Meeting V: Working With Federal Stakeholders. More: http://www.genome.gov/27553865.

By: GenomeTV

See the rest here:
GM5: Mission Health Personalized Medicine and Pharmacogenomics, Asheville, NC - Lynn Dressler - Video

Recommendation and review posted by sam

GM5: European Science Foundation #39;s Personalized Medicine Launch Event- Dan Roden
May 28-29, 2013 - Genomic Medicine Centers Meeting V: Working With Federal Stakeholders. More: http://www.genome.gov/27553865.

By: GenomeTV

See original here:
GM5: European Science Foundation's Personalized Medicine Launch Event- Dan Roden - Video

Recommendation and review posted by sam

PM 2.0 - An Integrated Approach to True Personalized Medicine Adoption
A webinar from Diaceutics on an Integrated Approach to True Personalized Medicine Adoption.

By: DiaceuticsLabceutics

Read more:
PM 2.0 - An Integrated Approach to True Personalized Medicine Adoption - Video

Recommendation and review posted by sam

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 11, 2013) - During the opening of the Personalized Medicine and Individualized Drug Delivery conference at the University of British Columbia today, the $50,000 Ronnie Miller Scholarship in Personalized Medicine was presented to a deserving student studying life sciences at the University. Mr. Ronnie Miller, past Chair of the Rx&D Board (2011) and President and CEO, Hoffmann-La Roche Limited, Dr. Roger Brownsey, Department Head, Biochemistry & Molecular Biology, Dr. Pieter Cullis, Professor, Biochemistry and Molecular Biology, and Mr. John Willow, Regional Director for British Columbia, Canada's Research-Based Pharmaceutical Companies (Rx&D) were on hand for the presentation.

"My colleagues and I in the Department of Biochemistry and Molecular Biology and the Faculty of Medicine at UBC are extremely grateful to Rx&D and Hoffmann-La Roche for their wonderful act of generosity and foresight in making this donation. The support of young trainees is critical and yet remains a continuing challenge. Providing such support for one of our brightest young scientists will pay huge dividends in the future and is one of the best investments we can make," said Dr. Brownsey.

The Scholarship was awarded to Joslyn Quick, who is focusing her work on the treatment of advanced prostate cancer in the hopes that treatments eventually be tailored to a patient's own genetic profile.

The Ronnie Miller Scholarship in Personalized Medicine has been created in honour of Mr. Ronnie Miller, past Chair of the Rx&D Board (2011) and President & CEO, Hoffmann-La Roche Limited. It was awarded to a graduate student of the Department of Biochemistry and Molecular Biology at the University of British Columbia, whose work will provide a significant contribution to the British Columbia Personalized Medicine Initiative (BCPMI). Rx&D and Hoffmann-La Roche Limited have each contributed $25,000, for a total of $50,000 over 5 years.

"I am very proud of this scholarship program, and am excited by what the next generation of scientists will do to further advance personalized healthcare," added Mr. Miller. "At Roche, personalized healthcare is about improving understanding of the disease and the patient to deliver precision medicine. It is about the right treatment at the right time for the right patient. To us, it means using the combined strength of our pharmaceutical and diagnostics arms to deliver better diagnosis, better treatments and, most importantly, better results."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

Read the original here:
Scholarship in Personalized Medicine Awarded at the University of British Columbia

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/gfvrg9/personalized) has announced the addition of the "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report to their offering.

Personalized Medicine is often defined as the right treatment for the right person at the right time. Personalized medicine is becoming the place to be in clinical diagnostics as well and slowly becoming the reality of future in the diagnostics industry.

Key Trends

By Technology Segment - Personalized Medicine diagnostics market is expected to grow with a double digit CAGR for the period of 2013 to 2018. It is expected that personalized medicine diagnostics market by technology is going to double by 2018 from its current market size in 2012. In this segment, Point of Care Testing and Molecular Diagnostics segments control the #1 and #2 positions in 2012.

By Diseases Segment - Personalized Medicine diagnostics market is expected to be more than US$ 30 Billion by 2018. Diabetes management test and Cancer management test are the leading market in this segment.

Renub Research report entitled Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing) report provides a comprehensive analysis of the emerging personalized medicine diagnostic market segments, including their dynamics, size, market share, key investors, clinical trials statement, technological trends, company analysis and a realistic future potential for personalized medicine in clinical testing. The report also entails major drivers and challenges of personalized medicine diagnostic market.

Key Topics Covered

1. Executive Summary

2. Worldwide Personalized Medicine Diagnostic Market & Forecast

Here is the original post:
Research and Markets: Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation ...

Recommendation and review posted by sam

NEW YORK, June 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Personalized Medicine Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment http://www.reportlinker.com/p01361264/Personalized-Medicine-Market---A-Strategic-Analysis-of-Industry-Trends-Technologies-Participants-and-Environment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 239 tables & figures.

The personalized medicine (global) market is presented as follows:

By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, CELERA, MYRIAD) By Geography (US, UK, EU) By Segment (Targeted therapeutics, Esoteric tests, Esoteric lab services) By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

Up-to-date company financials, sales & revenue figures Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies Business Model Strategies for Providers. Provider Systems and Academic Medical Centres Business Model Strategies for Payers & Governments Private and Public Funding and Personalized Medicine Reimbursement Revisions to Current Payment Systems and intellectual property How to Gain Market Penetration in the EU Cost-effectiveness and Business Value of Personalized Medicine Consumer genomics and POC market Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) Top fastest growing market segments and emerging opportunities Top pharmaceutical companies within the IPM by market share and revenue Comprehensive product portfolios, R&D activity and pipeline therapeutics M&A activity and future strategies of top personalized medicine pharmacos Personalized Medicine Regulation (UK, Germany, France, Spain, Italy) CE-marked Personalized Medicine/Diagnostic Tests FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy.

Excerpt from:
Personalized Medicine Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

Recommendation and review posted by sam

Project Walk Carlsbad - Alton P. Spinal Cord Injury Milestone
Alton P. has a C6 spinal cord injury that he suffered in 2009. This is his second visit to our Carlsbad location and he is seeing great progress. Here you can see him getting himself into a...

By: Project Walk

See the article here:
Project Walk Carlsbad - Alton P. Spinal Cord Injury Milestone - Video

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/hls5jn/acute_spinal_cord) has announced the addition of the "Acute Spinal Cord Injury - Pipeline Review, H1 2013" report to their offering.

'Acute Spinal Cord Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury.

Scope

- A snapshot of the global therapeutic scenario for Acute Spinal Cord Injury.

- A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Acute Spinal Cord Injury pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

See the original post:
Research and Markets: Acute Spinal Cord Injury - Pipeline Review Report, H1 2013 Edition

Recommendation and review posted by sam

QStraint will be the first product sponsor for the 50 Ability Marathon, an event raising funds for spinal cord injury research.

For the 50 Ability Marathon, a team of three wheelchair racers are attempting to compete in 50 marathons in 50 states in 50 weeks to raise funds for the Christopher & Dana Reeve Foundation, which is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for people living with paralysis through grants, information and advocacy. What these three wheelchair racers are trying to achieve is a testament to their strength and courage, said Dan Bruck, QStraint marketing manager. We are proud to be part of their journey in bringing awareness to and raising funds for the Christopher & Dana Reeve Foundation.

As part of the sponsorship QStraint will outfit the three wheelchairs with backpacks and provide promotional materials for the rehabilitation centers where the trio visit at each race location.

The trio of wheelchair racers is made up of Paul Erway from Kentucky and Grant Berthiaume and Aaron Roux of Arizona. Erway severely injured his spinal cord in a car accident. Berthiaume was paralyzed from the waist down in a construction accident. Roux was left with quadriplegia following a car accident while on leave from the U.S. Marine Corps.

Erway, Berthiaume and another friend came up with the idea of racing in 50 marathons in 50 states in 50 weeks while racing in the Oita International Wheelchair Marathon in Japan, the worlds premiere wheelchair marathon, in 2010. We want to set an example for others with disabilities to help them see through the fog of their challenges so they can focus on the clarity of living life to the fullest, said Erway. My hope is that people see what we do and get the hint realizing that their disability isnt the end of their lives. We appreciate QStraints support of this mission.

For more information about 50 Ability Marathons visit http://www.50abilitymarathons.com/category/marathons/.

RELATED: "Para-athlete named Q'Straint brand ambassador."

Go here to read the rest:
Q'Straint sponsors fundraiser for spinal cord injury research

Recommendation and review posted by sam

Progress of ASCENT-ASCI Phase 2 Trial of SUN13837 Discussed at American Spinal Injury Association Symposium

PARAMUS, N.J. , July 8, 2013 /CNW/ - Asubio Pharmaceuticals, Inc. today announced the expansion of enrollment for its ASCENT-ASCI (Asubio Spinal Cord Early Neuro-recovery Treatment for Acute Spinal Cord Injury) trial to include AIS A, B and C injury to the cervical spine. ASCENT-ASCI is a Phase 2 clinical trial evaluating SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury. Asubio recently discussed the expanded inclusion criteria and progress of the study at a peer-attended symposium at the American Spinal Injury Association ( ASIA ) 40th Anniversary annual meeting in Chicago , Illinois .

The company is currently working with 45 acute trauma centers throughout the United States and Canada and plans to increase that number to 55. Trauma centers must first sign up to participate in the clinical trial and then brief attending trauma physicians and nurses on how to rapidly identify eligible spinal cord injury patients when they first arrive at their facility. In addition to the 45 acute trauma centers, there are also 13 stand-alone rehabilitation centers participating in the study. Interested physicians or trauma/rehabilitation center representatives should contact Ben Levinson at blevinson@asubio.com for more information regarding ASCENT-ASCI trial participation, or visit ClinicalTrials.gov (NCT01502631).

"The recent adoption of a more inclusive Asubio trial protocol will meet the needs of a broader number of spinal cord injuries and enable a more sensitive and accurate determination of therapeutic benefit across a wider range of functional disability," said John Steeves , PhD, Peter Wall Distinguished Scholar in Residence, Professor and Founding Director of ICORD (International Collaboration On Repair Discoveries). "I encourage major trauma centers to consider participation and informing and enrolling appropriate patients."

"It takes a small community to pull off an acute spinal cord injury study, but with a bit of planning, it can be done," explained Laura Wollenweber , a clinical research coordinator at the Medical College of Wisconsin in Milwaukee , who spoke of her experience enrolling patients in the study. Dr. Levinson added: "Of course, cautious optimism is warranted, but we are hopeful that the broadened enrollment criteria will bring new hope for a wider range of patients suffering from this devastating, life-altering type of trauma."

About SUN13837

SUN13837 has been without significant side effects in Phase 1 studies in healthy subjects. Experimental evidence has shown SUN13837 to have both neuroprotective and axonal outgrowth properties using both invitro studies and animal models of spinal cord injury. In these models, SUN13837 administration improved corticospinal neuron survival and axonal regrowth, resulting in statistically significant functional recovery relative to placebo. The preclinical evidence supports the concept that potential drug benefits will be due to 1) neuroprotection by limiting the degree of primary mechanical damage at the injury site, 2) augmentation of axonal outgrowth in the otherwise unfavorable post-injury microenvironment, and 3) facilitation of functional neural plasticity within surviving and newly formed neural circuits.

"SUN13837 is expected to provide neuroprotection from glutamate excito-toxicity and promote axonal outgrowth, which is often inhibited after spinal cord injury," said Benjamin Levinson , M.D., Senior Director of Medical and Scientific Affairs at Asubio. "It is similar in mechanism to basic fibroblast growth factor (bFGF) but without the troublesome complication of stimulating cell proliferation. Like bFGF, SUN13837 is thought to bind with FGF receptors to induce the intracellular signaling events providing its positive properties. Unlike bFGF (a large protein), SUN13837 is a highly lipid soluble small molecule that can be easily and reliably administered through peripheral intravenous injection."

About Asubio

Asubio, a group company of Daiichi Sankyo, is committed to building a brighter, healthier tomorrow by developing ethical pharmaceuticals that improve the health and wellbeing of people with unmet medical needs around the world. Asubio Pharmaceuticals, located in Paramus, New Jersey , is the U.S. subsidiary of Asubio Pharma Company, Limited, which is based in Kobe , Japan . Asubio Pharmaceuticals, Inc. is a research-based pharmaceutical company involved in the development of drug compounds from Phase 1 clinical trials through Phase 2 proof of concept. In early 2012 Asubio initiated a new Phase 2 clinical study in patients with newly diagnosed acute spinal cord injury, to determine whether the investigative new drug SUN13837 improves neurological function in this catastrophic injury.

Read more:
Asubio Broadens Inclusion Criteria For Landmark Spinal Cord Injury Clinical Trial

Recommendation and review posted by sam

Earlier this week the House of Lords' ScienceandTechnologyCommitteepublished a report in which it said that the UK is "currently underprepared to realise the full potential of regenerative medicine".

Among the criticisms the Committee raised was with the regulatory regime that applies in the UK to regenerative medicines and with the level of Government funding to help the industry grow.

Life sciences transactions lawyer Allistair Booth of Pinsent Masons, the law firm behind Out-Law.com, said that the Government had demonstrated its commitment to the growth of regenerative medicines research in the UK.

"Regenerative medicines is one of the next big areas for medical research," Booth said. "The Government has put together centres of excellence around cutting edge technology with the idea of combining research and catapulting it forward. The Cell Therapy Catapult is one of the centres set to benefit from the Chancellor's decision to ring fence 185 million for scientific research in his recent Spending Review."

"Through, for example, the Cell Therapy Catapult and the government funding of that Catapult, small regenerative medicine research companies can get access to equipment, expertise and the other resources that would most likely otherwise be beyond their reach," he said. "The reality is that, while a number of early stage venture funds have been created in the last few years and that is a very welcome development there is still a shortage of early stage investment capital to assist these companies to take forward such cutting edge innovation."

"Through its investment in the various Catapults and the BioMedical Catalyst fund the UK Government is providing vital, meaningful and very welcome support to innovative life sciences companies to move forward their research to the point where it can attract further investment or partnering opportunities," said Booth.

In its report, the ScienceandTechnologyCommitteesaid it was concerned that the Cell Therapy Catapult was "seeking to achieve too much, too quickly, given the level of funding" available to it. The Cell Therapy Catapult, set up in 2012, had an initial budget of approximately 70m to be spread over five years, but the Committee said that it should prioritise "developing investable propositions and building connections" before sharing its expertise.

The Committee also said that "innovative funding models" should be explored to help support the development of regenerative medicines research. It said the models would likely rely on the Government matching funds pledged or providing a form of guarantee to investments and that the Government should "put their money where their mouth is".

The Committee also called for action to help reduce regulatory barriers to the development of the regenerative medicines research in the UK. It said that the Health Research Authority (HRA) must "simplify the regulatory route so that the development of regenerative medicine, and other innovative therapies, is not hindered". A new independent advisory group should be set up to assist the HRA in helping "focus and clarify the functions of regulators".

Life sciences expert Louise Fullwood of Pinsent Masons said she agreed with the Committee's view that the existing regulatory framework was 'labyrinthine'.

Follow this link:
Streamlined regulation would be welcome but Government clearly supports regenerative medicines research, say experts

Recommendation and review posted by sam

NEW YORK, July 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative Medicines: Bone and Joint Applications http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

INTRODUCTION

Regenerative medicine in orthopedic applications is a $2.7 billion per year niche sector in America's $2.6 trillion per year healthcare system. However, it is a sector of immense interest in terms of technical and medical possibilities. The best analogy to the current state of regenerative therapies in the bone and joint healing sector is the nascency of the microprocessors business back in 1971. At that time, microprocessors (namely Intel's 4004), and related innovations, were just an infinitesimal segment of electronic component sales, but this innovation came to dominate the economy. The regenerative therapies sector, particularly areas such as cell therapy and stem cell derived products is in a comparable position today.

The regenerative medicine industry has been in existence for nearly 25 years. Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2.7 billion in economic activity in 2013, of which venture capital and R&D funding accounts for about $145 million. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003 and even since the most recent edition in 2009. Innumerable buyouts, consolidations, product abandonments, new firms and a few bankruptcies, too, have occurred in just the last several years. These changes are reflected in the Company Profiles section of this report. In addition, intensive R&D efforts at universities, the National Institutes of Health, the National Science Foundation and at FDA centers that focus on cuttingedge technology underscore the importance of this industry.

Regenerative therapies have the potential to improve medical outcomes, enhance quality of life, and reduce overall healthcare costs. A key objective is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and, particularly, biomedical engineering.

The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stemcell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinalcord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.

OBJECTIVES AND GOALS OF STUDY

This report focuses on the bone and jointrelated applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the fiveyear forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone and cartilagegrowthstimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

Profiles are provided of leading and emerging companies in the bone and joint regenerative medicine markets, along with analyses of the current and future positioning of their products and businesses in this active and rapidly changing market. Developmental and clinical stage companies are well covered.

Read more:
Regenerative Medicines: Bone and Joint Applications

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/23dgtg/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering.

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement.

This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.

The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

Key Topics Covered

1. Overview

2. Regenerative Medicines: An Overview of Segments

3. Regenerative Medicine: The Next Evolution of Medical Treatment

4. Recent Advances in Regenerative Medicine and Stem Cell Research

Read the original:
Research and Markets: Regenerative Medicine Markets - 2013 Report

Recommendation and review posted by sam

by Rappler.com Posted on 07/09/2013 9:42 PM |Updated 07/10/2013 3:51 PM

MANILA, Philippines - Everyone is talking about stem cell therapy. But scammers and swindlers are also taking advantage of the fad, prompting the Health Department to step in. Buena Bernal reports.

Its the new medical buzzword in the Philippines. Stem cell therapy is a procedure which uses repair cells found in the body to replace old cells. Dr Florencio Lucero started doing the procedure 6 years ago.

DR FLORENCIO LUCERO, STEM CELL TRANSPLANT SURGEON: Stem cells can help degenerative diseases. Some people who have serious illnesses, and they cannot find any solution to their condition, they seek this kind of treatment, because it can improve their condition. But not a cure. It cannot cure.

Pilar Vazquez who went through a mild stroke says she felt energized after undergoing the treatment.

PILAR VAZQUEZ, STEM CELL TRANSPLANT PATIENT: Stem cell is very good. I did not feel pain or what. Everything is very good. Before, I dont [always] talk. Now, I always talk. Thats a very good difference, because now they say, Ay si Mommy, ang galing galing niyan, parating nagsasalita!

But stem cell therapy became controversial after 3 government officials allegedly died from the treatment, while another official filed charges against his German doctor for his botched treatment last year. Food and Drug Administration director Dr. Kenneth Hartigan Go says right now, stem cell therapy is allowed but under investigation.

DR KENNETH HARTIGAN-GO, DIRECTOR, FOOD AND DRUG ADMINISTRATION: We are keeping an objective mind and saying, okay, if this is investigational, go ahead. And then we have to see outcome, say, within a period of a time whether the product actually works or not.

The Department of Health cautions the public from engaging in prohibited forms of the treatment -- those that are performed outside accredited facilities and those that source stem cells from human embryos. Health Secretary Enrique Ona says he does not want to stifle the innovation but there must be regulation.

Follow this link:
Stem cell therapy: Future of medicine?

Recommendation and review posted by simmons

DANVERS, Mass.--(BUSINESS WIRE)--

Cell Signaling Technology, Inc. (CST) announced today the issuance of a key US patent, 8,481,279, which relates to methods for inhibiting the progression of lung cancers that express the EML4-ALK fusion gene. The ALK fusion gene is an alteration or defect in a normal gene called anaplastic lymphoma kinase (ALK) that is thought to play a critical role in the growth of some non-small cell lung cancers (NSCLCs) and has been central to the development of several promising new, targeted cancer therapeutics.

CST has quietly pursued an aggressive research agenda over the last decade to understand the underlying mechanisms of disease progression, with an intense focus on cancer for the drug discovery industry and our customers, said Michael J. Comb, Ph.D., President and CEO of CST. We have assembled world-class scientists, detection systems and bioinformatics capabilities, investing over 20% of revenue to further research and development into the biochemical aberrations that underlie disease and the companion diagnostics and therapies to combat it.

CST has previously been issued patents (8,377,642, 8,288,102, 8,232,060, 8,168,383, and 7,700,339) covering methods for detecting the EML4-ALK fusion, which has been reported in a subset of patients with breast, colon and non-small cell lung cancer (NSCLC). CST now has a dominant IP position for EML4-ALK in NSCLC that spans from research through diagnosis and therapy.

CST was one of two groups that independently discovered that rare lung adenocarcinomas contain rearrangements of theALK gene that result in the pathologic expression of a fusion protein, most commonly EML4-ALK. CST is unique in the industry as its research agenda is completely self-funded. Privately held and scientist led, CST leverages what is widely regarded as the highest quality antibody portfolio commercially available, a byproduct of the companys research, to further its disease research agenda. The company regularly shares the results of its findings with the research community via high-impact journal publications (Cell, Nature Biotechnology et al.) and its ongoing, deep collaborations with academia and industry.

CST is proud to be part of one of the most elegant examples of translational research and personalized medicine that I have seen: a discovery going from a patient to the lab and back to patients, all within the space of two years, according to Mary Pinder-Schenck, M.D., in an article about the ALK story in Cancer GRACE.

Lung cancer is the worlds leading cause of cancer death, with more than 1.8 million new cases diagnosed each year, 85% of which are NSCLC. Approximately 3-5% of NSCLC patients have tumors positive for the ALK fusion gene. Patients are usually diagnosed with advanced disease and have a very low survival rate. Recently Pfizers Xalkori (crizotinib) was approved in the US for treatment that targets patients with the ALK fusion and several companies have additional therapeutics in various clinical trial stages.

About Cell Signaling Technology, Inc.

Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. Its why we produce all of our antibodies in house, and perform painstaking validations for multiple applications. And the same CST scientists who produce our antibodies also provide technical support for customers, helping them design experiments, troubleshoot, and achieve reliable results. We do this because thats what wed want if we were in the lab. Because, actually, we are.

For more information visit cellsignal.com.

Link:
Cell Signaling Technology Awarded Patents Critical to Lung Cancer Therapy

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d2p5hw/neuroprotection) has announced the addition of Jain PharmaBiotech's new report "Neuroprotection - Drugs, Markets and Companies" to their offering.

This updated report now contains even more company profiles than the previous edition!

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.

Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.

The report contains profiles of 137 companies that have a neuroprotective product or products along with 121 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 1,000 references are included. Clinical trials of various neuroprotective agents are described and failures of trials are analyzed with suggestions for improving the selection of drugs and design of trials. The report is supplemented with 67 tables and 13 figures.

Market analysis of currently used products that have a neuroprotective effect are analyzed for the year 2012. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2017 when it will constitute a major and important component of the CNS market. Forecasts are made until 2022. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.

Key Topics Covered:

Part I: Drugs & Markets

Executive Summary

Read more from the original source:
Research and Markets: Neuroprotection - Drugs, Markets and Companies - 2013-2022

Recommendation and review posted by Bethany Smith

Public release date: 9-Jul-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- Next-generation hydrogels can form synthetic scaffolds to support the formation of replacement tissues and organs in the emerging area of regenerative medicine. Embedding peptides into the hydrogels stimulates the growth of essential microvascular networks to ensure a good blood supply. Novel, cutting-edge technology in which hydrogels functionalized with laminin-derived peptides were transplanted in a mouse cornea and were shown to support cell growth and blood vessel formation is described in an article in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResarch Open Access website.

Saniya Ali and coauthors from Rice University and Baylor College of Medicine, Houston, TX, and Duke University, Durham, NC, created a biodegradable hydrogel-based scaffold containing laminins. These peptides are key components of cells' extracellular matrix and play a critical role in the attachment, movement, and organization of endothelial cells, which form the lining of tubules such as blood vessels. Stimulating and controlling the formation and growth of these tubule-like, cell-lined structures is essential for ensuring sufficient blood supply to support large complex tissues or organs. The authors present their work and the results of animal studies in the article "Immobilization of Cell-Adhesive Laminin Peptides in Degradable PEGDA Hydrogels Influences Endothelial Cell Tubulogenesis."

"Enhancing vascularization in synthetic scaffolds is essential to support the formation of blood vessels in engineered tissues," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "The work in this study demonstrates that laminin-derived peptide sequences immobilized in synthetic scaffolds can be used to regulate the formation of microvasculature in tissue-engineered constructs."

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResarch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including, DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Read the original:
Method to improve blood supply to engineered replacement tissues

Recommendation and review posted by Bethany Smith

Arcadia, CA (PRWEB) July 09, 2013

Retina Institute (RIC) now offers RetnaGene, a genetic test to evaluate the risk of a patient with early age-related macular degeneration (AMD) progressing to advanced choroidal neovascular disease within 2, 5, and 10 years. Efficient monitoring of this chronic disease greatly reduces the chances of partial or complete loss of vision in patients.

"RetnaGene testing represents the leading edge of clinically impactful genetic medicine in ophthalmology, stated RIC surgeon, Joshua Hedaya, MD. This technology will fundamentally improve our ability to treat and prevent vision loss from AMD. It is a very exciting time for doctors and patients alike."

The reported risk scores for developing CNV are based on four risk factors including genotype, phenotype, age and environmental factors such as smoking.

With the information provided by the RetnaGene test, RIC can customize an approach to monitoring and treatment for each individual patient based on their reported risk scores for disease progression. This provides a tremendous advantage when managing a condition such as AMD, in which loss of vision is often severe, unpredictable, and variably responsive to treatment.

With this test, RIC can safely reduce the screening burden for lower risk patients, many of whom may have difficulty complying with frequent office visits. This additional genetic data point allows for a more informed decision regarding initiation of treatment in patients with equivocal findings on standard diagnostic tests.

For further information about RetnaGene or to refer a patient to RIC for AMD screening, please contact RIC at 800-898-2020. Testing is available at all RIC locations, and is performed at no or minimal cost to patients.

About Retina Institute The Retina Institute was founded on a model of exceptional patient care and clinical excellence and is recognized as one of the nations leading practices specializing in vitreoretinal diseases. With 15 highly-trained retina surgeons in 24 centers, Retina Institute is committed to innovation, compassion and superior results, and works in close partnership with each other and with referring doctors to achieve the best possible outcome for every patient. For more information visit retina2020.com.

###

Read the rest here:
Retina Institute of California Advances Genetic Diagnostics for Treatment of Age-related Macular Degeneration (AMD)

Recommendation and review posted by Bethany Smith

NEW YORK & LOS ANGELES--(BUSINESS WIRE)--

Scil is launching a service, the first of its kind, that allows individuals to benefit from 2012 Nobel Prize-winning medical research to store a backup of their adult selves literally freezing their healthy cells in time. Scils world-leading experts use cutting-edge techniques to take cells from a small sample of an individuals skin and reboot them at the "Day Zero state". These skin cells are processed into stem cells (iPS) that are stored long-term for potential future uses, which could repair damaged organs, rebuild tissue or fight disease, as personalised genetic-based medicine continues to develop.

Andr Choulika, CEO of Scil, said: Scil offers people the best possible chance in the future. People should be able to live young, no matter how old they grow. Scil gives them the opportunity to take advantage of the wave of regenerative medicine. Were offering the potential for people to use their cells for their cure as soon as regenerative medicine treatments become available.

iPS (induced pluripotent stem cells) are capable of developing into any cell type. They can be derived from adult cells at any time of life, but given the fast rate at which cell DNA degenerates (the human body accumulates about 1.8 million DNA mutations per second), Scils experts recommend taking this step sooner rather than later to ensure the healthiest possible cells are stored.

With the Scil service, the iPS cells are stored at -180C for as long as needed for potential future use as soon as regenerative medicine treatments become available. It is the first time ever that such a service has been made available to individuals commercially.

Regenerative medicine is the process of replacing or regenerating human cells, tissues and organs to restore or establish normal function or, by stimulating the body's own repair mechanisms, to heal previously irreparable tissues or organs.

The service is very simple and painless for the individual. A skin tissue sample is taken under local anaesthetic and by arrangement at your convenience. The skin cells are then rebooted into iPS cells by Scils world-leading biotechnology teams; and finally they are stored by Scil for a lifetime in cutting-edge laboratory conditions until they are needed for future medical applications as soon as they become available.

You can read more about Scil, the benefits of stem cell banking, and the leading role its parent company Cellectis plays in genetic research at http://www.sceil.com

About Scil

Scil, part of the Cellectis Group, delivers a service that allows individuals to freeze their adult stem cells and harness the future potential of regenerative medicine. Based on Nobel Prize-winning research, Scils world-leading experts use cutting-edge techniques to take cells from a small sample of an individuals skin and reset them at the Day Zero state. These skin cells are processed into induce pluripotent stem cells (iPS) that are stored long-term for potential future needs to repair damaged organs, rebuild tissue and fight disease as personalised genetic-based medicine continues to develop. For further information about Scil, please visit http://www.sceil.com

See original here:
Scéil Launches World’s First iPS Stem Cell Back-up Service

Recommendation and review posted by Bethany Smith

An in vitro fertilization (IVF) milestone has been announced by British researchers. For the first time, a baby was born using a new embryo screening technique combs through genetic data looking for risk for diseases and other abnormalities. The researchers say the technique, known as "next generation sequencing" will revolutionize embryo selection for families turning to IVF.

Play Video

"In the past few years, results from randomized clinical trials have suggested that most IVF patients would benefit from embryo chromosome screening, with some studies reporting a 50 percent boost in pregnancy rates. However, the costs of these genetic tests are relatively high, putting them beyond the reach of many patients," lead researcher Dr. Dagan Wells, a scientist at the NIHR Biomedical Research Centre at the University of Oxford in the U.K., said in a statement. "Next generation sequencing is a way which could make chromosome testing more widely available to a greater number of patients, improving access by cutting the costs."

Wells presented the case study of the first birth Monday at the European Society of Human Reproduction and Embryology in London.

Play Video

Next generation DNA-sequencing technology is used in other areas of medicine, such as in research of differences between normal cells and cancer cells, according to the Columbia Genome Center in New York City. For the process, DNA is broken into small fragments which are turned into strings of genetic code which are then sequenced in hundreds of millions parallel reactions.

This testing can also reveal information on the chances for inheriting genetic disorders, chromosome abnormalities and mitochondrial disease, mutations within a cell's nucleus that could lead to conditions including heart disease, motor disorders, diabetes, respiratory problems, seizures, and vision and hearing problems.

Wells said since the technology is already revolutionizing diagnostic medicine, if it's applied to embryo selection for IVF, it can provide "an unprecedented insight into the biology of embryos."

That's important, because only about 30 percent of embryos currently selected for transfer in IVF actually implant in the uterus. The reason for this high failure rate is unknown, according to the researchers, but they suspect hidden genetic mutations and abnormalities may be at play.

To ensure the new technique's accuracy, the researchers sequenced cells from 45 embryos that had previously been shown to be abnormal by a different testing technique. In a blind comparison of the two techniques, high accuracy was established.

Go here to read the rest:
IVF first: Baby born with embryo selection from DNA screening

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/96mtm2/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.

This updated 2013 report now features even more company profiles and collaborations!

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment. Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping. A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2012-2022.

Profiles of 283 companies involved in developing technologies for personalized medicines, along with 504 collaborations are included in the part II of the report. Finally the bibliography contains over 650 selected publications cited in the report. The report is supplemented by 65 tables and 18 figures.

Key Topics Covered:

Part I: Scientific & Commercial Aspects

Read the original post:
Research and Markets: Personalized Medicine Report - Scientific and Commercial Aspects - 2013-2022

Recommendation and review posted by Bethany Smith

LIVINGSTON, NJ--(Marketwired - Jul 9, 2013) - Reprogenetics, one of the largest providers of preimplantation genetic diagnosis (PGD) services announced today that one of their researchers Dr. Dagan Wells of the NIHR Biomedical Research Centre at the University of Oxford, UK, Reprogenetics UK and Reprogenetics LLC, has been acknowledged by the European Society of Human Reproduction and Embryology (ESHRE), in London, UK for his work in the area of Next Generation Sequencing (NGS). His research led to the first ever successful birth of a baby through this unique science revealing extensive genetic information derived from human embryos. This impressive science can significantly impact the process for, and success rate of, embryo selection for in vitro fertilization in the future.

"Reprogenetics congratulates Dr. Wells on his outstanding accomplishment to genetic analysis and achieving this monumental goal in the reproductive space," said Dr. Jacques Cohen, Reprogenetics Scientific Director. "We are proud of the quality team we have established including Dr. Wells who all play an integral role in us reaching the goal of predicting viability of embryos with our NGS technique, and what it can ultimately mean for patients."

About the studyTo test the accuracy and predictability of NGS, the international study conducted in the UK in collaboration with IVF clinics in the USA used a technique that has never before been applied in the screening of human embryos. The study looked at multiple cells from cell lines known to have chromosomal abnormalities, genetic defects (cystic fibrosis), or other mutations (n=30). Further, in a blinded portion of the study, investigators used the new NGS technique to re-examine 45 embryos in which abnormalities had previously been identified by other methods. Once the accuracy of the new technique was demonstrated, it was applied clinically, with cells sampled from seven five-day old embryos produced by two couples undergoing IVF. The mothers were 35 and 39 years old, and one had a history of miscarriage (total 82 embryos).

The outcome validated the NGS technique, with 100% of samples yielding results (82/82). NGS accurately identified abnormalities in those cells that had been previously identified as having them. And, in the clinical setting, NGS revealed 3/5 viable embryos from the first couple and 2/2 from the second. Single embryo transfers based on these results led to healthy pregnancies for both couples. The first pregnancy ended with the delivery of a healthy boy, Connor Levy, last month and the other is ongoing.

Dr. Wells noted that the cost of NGS, which enables simultaneous testing for a variety of abnormalities, is significantly lower than that of existing screening methods, suggesting that this technique may ultimately bring genetic analysis within reach for a much larger number of patients.

"We greatly admire the vision, drive and perseverance demonstrated by Dr. Wells and his team. This study validates an important new approach to genetic analysis, and we look forward to working with them and pursuing this research further," said Dr. Jamie Grifo, of NYU and a participant in the study.

About Embryo ScreeningAccording to ESHRE, on average, only about 30% of embryos selected for transfer actually result in a viable pregnancy. Although the precise reason is unknown, researchers believe that unidentified genetic or chromosomal abnormalities are in part responsible for this low success rate. Genetic screening methods introduced in recent years are helpful, but still have multiple drawbacks when used in a clinical setting.

About PGS In PGS, embryos created through in-vitro fertilization are tested for chromosomal abnormalities prior to replacement in a woman's uterus. This process allows the reproductive endocrinologist to select only chromosomally healthy embryos for replacement with the goal of increasing the chance of successful implantation, reducing spontaneous abortion, reducing the chance for a fetus to have a chromosomal abnormality and improving delivery rates for assisted reproduction.

Chromosome abnormalities are the primary cause of miscarriage and failure to implant. This percentage increases with maternal age, and studies have shown that 82% of embryos from women 40 years and older will be chromosomally abnormal. However, once normal (euploid) embryos are selected, they implant equally well at any age up to 42 years of age.

About ReprogeneticsReprogenetics is a genetics laboratory specialized in Reproductive Medicine and a pioneer and Preimplantation Genetic Diagnosis (PGD). Dr. Santiago Munn and Dr. Jacques Cohen founded Reprogenetics in the year 2000 after extensive experience in PGD and IVF, with more than 24,000 PGD procedures performed so far, and with branches in 7 countries. Reprogenetics offers a comprehensive and personalized service to its referring IVF centers and their patients. Genetic counselors are intricately involved in the process and interact routinely with the patients pursuing all PGD tests.

Originally posted here:
First Ever Baby Born Through Genetic Derived Human Embryos

Recommendation and review posted by Bethany Smith

LOS ANGELES--(BUSINESS WIRE)--

The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection, utilizes a gene medicine called Cal-1, developed in the lab of Nobel Laureate Dr. David Baltimore and by Calimmune.

In the study, 12 HIV-positive participants will be infused with their own T cells and stem cells (hematopoietic stem cells, HSC), which have been modified to block the HIV receptor CCR5, and to prevent HIV fusion. The procedure is designed to prevent the virus from entering and damaging protected cells. The dual approach used in the study is designed to reduce the possibility that HIV can develop resistance to the procedure.

The goal of the study is to assess the safety, feasibility and tolerability of Cal-1 in HIV-infected individuals who have previously been on highly active antiretroviral therapy (HAART) but are not currently taking any antiretroviral agent. In addition to routine clinical and laboratory assessments to monitor general health and HIV infection, the study will monitor the presence of Cal-1 protected cells in various cell types in the blood and lymphoid tissue. Other analyses will monitor the safety of Cal-1. The first patient was treated in the study in late June. Data from this study are expected in 2015.

All participants in the studys three arms will receive the Cal-1 gene transfer. Participants in two of the three study arms will also receive different doses of a preconditioning drug known as busulfan, which may make the therapy more effective.

This study is an early but important step in an emerging area of scientific exploration, representing the culmination of more than a decade of research and development, said Calimmune Chief Executive Officer Louis Breton. We are optimistic that what we learn from this study may bring us closer to the day when a one-time treatment could provide an alternative to a lifetime of antiretroviral therapy.

The study has been partially funded by the California Institute for Regenerative Medicine (CIRM). The study will take place at clinical trial sites in Los Angeles and San Francisco, Calif., under the direction of Principal Investigators Ron Mitsayasu, M.D., of UCLA and Jacob P. Lalezari, M.D., of Quest Clinical Research.

For more information, visit http://www.clinicaltrials.gov.

About Calimmune

Calimmune is a clinical-stage HIV gene medicines company focused on developing innovative cell-based therapies for HIV. The companys stem cell technology was discovered in the labs of Nobel Laureate Dr. David Baltimore (Caltech) and Dr. Irvin Chen (UCLA AIDS Institute). Calimmune is also developing a rich product candidate pipeline to address the needs of different types of individuals at different states of HIV infection and with different levels of treatment experience.

Read the rest here:
Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

Recommendation and review posted by Bethany Smith

Shotgun Flash - Apex Genetics on Esamir
A good run on my shotgun flash -- http://www.twitch.tv/lepalose/c/2512624 utm_campaign=archive_export utm_source=lepalose utm_medium=youtube.

By: Lepalose

See original here:
Shotgun Flash - Apex Genetics on Esamir - Video

Recommendation and review posted by Bethany Smith